Claims for Patent: 10,639,308

Summary for Patent: 10,639,308

Title:	sGC stimulators
Abstract:	Compounds of Formulae I\' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. ##STR00001##
Inventor(s):	Nakai; Takashi (Newton, MA), Moore; Joel (Lexington, MA), Perl; Nicholas Robert (Somerville, MA), Iyengar; Rajesh R. (West Newton, MA), Mermerian; Ara (Waltham, MA), Im; G-Yoon Jamie (Cambridge, MA), Lee; Thomas Wai-Ho (Lexington, MA), Hudson; Colleen (Denver, CO), Rennie; Glen Robert (Somerville, MA), Jia; Lei (San Diego, CA), Renhowe; Paul Allan (Sudbury, MA), Barden; Timothy Claude (Waltham, MA), Yu; Xiang Y. (Acton, MA), Sheppeck; James Edward (Newtown, PA), Iyer; Karthik (Cambridge, MA), Jung; Joon (Newton, MA), Milne; George Todd (Brookline, MA), Long; Kimberly Kafadar (Boston, MA), Currie; Mark G. (Sterling, MA)
Assignee:	Cyclerion Therapeutics, Inc. (Cambridge, MA)
Application Number:	16/178,771

Details for Patent 10,639,308

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	October 28, 1982		2038-11-02
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	December 29, 2015		2038-11-02
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	August 06, 1998		2038-11-02
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	March 31, 1994		2038-11-02
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	May 25, 2018		2038-11-02
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	June 25, 1991		2038-11-02
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	June 01, 2018		2038-11-02